Q1 Earnings Forecast for GANX Issued By Roth Capital

Gain Therapeutics, Inc. (NASDAQ:GANX) – Equities researchers at Roth Capital issued their Q1 2026 EPS estimates for shares of Gain Therapeutics in a research note issued to investors on Sunday, March 30th. Roth Capital analyst B. Pachaiyappan forecasts that the company will earn ($0.27) per share for the quarter. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics’ Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.27) EPS and Q4 2026 earnings at ($0.30) EPS.

Several other research analysts also recently commented on GANX. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday, March 17th. Roth Mkm restated a “buy” rating and set a $7.00 target price on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Scotiabank started coverage on shares of Gain Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price target for the company. Finally, Chardan Capital restated a “buy” rating and set a $6.00 price objective on shares of Gain Therapeutics in a research report on Friday. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $8.20.

Gain Therapeutics Price Performance

NASDAQ GANX opened at $1.91 on Tuesday. The business’s fifty day moving average is $2.21 and its 200 day moving average is $2.07. Gain Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $4.04. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The company has a market capitalization of $50.66 million, a PE ratio of -1.74 and a beta of 0.14.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.07.

Institutional Investors Weigh In On Gain Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Sprott Inc. bought a new position in shares of Gain Therapeutics during the fourth quarter worth $30,000. Benedict Financial Advisors Inc. bought a new position in shares of Gain Therapeutics during the 4th quarter valued at about $35,000. Bridgeway Capital Management LLC bought a new position in shares of Gain Therapeutics during the 4th quarter valued at about $65,000. Northern Trust Corp grew its position in shares of Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after purchasing an additional 39,642 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Gain Therapeutics in the fourth quarter worth about $198,000. Institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.